CTLA4 and neoplasm: In one of these studies, the combination of imatinib that can reduce tumor cell expression of IDO and thus, block IDO-mediated immunosuppression of T cell responses, with anti-CTLA-4 mAb resulted in enhanced antitumor response in a mouse model of gastrointestinal tumors [173].